# Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Study · id `cardio:ct-nct04755283` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04755283](<https://clinicaltrials.gov/study/NCT04755283>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04755283

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1287 participants.

## Technical summary

Registry record NCT04755283. Randomized; triple masking; primary purpose supportive care. Start 2021-02-02 (actual); primary completion 2024-02-15 (actual). Results posted on 2025-07-30.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose supportive care
- Phase: Phase 2
- Enrolled: 1287 participants (enrolled count; ClinicalTrials.gov record NCT04755283, source copy `cardio:ctgov-nct04755283-2025-11-06`, retrieved 2026-10-26)
- Started: 2021-02-02 (actual) (ClinicalTrials.gov record NCT04755283, source copy `cardio:ctgov-nct04755283-2025-11-06`, retrieved 2026-10-26)
- Primary completion: 2024-02-15 (actual) (ClinicalTrials.gov record NCT04755283, source copy `cardio:ctgov-nct04755283-2025-11-06`, retrieved 2026-10-26)
- Completion: 2028-12-29 (anticipated) (ClinicalTrials.gov record NCT04755283, source copy `cardio:ctgov-nct04755283-2025-11-06`, retrieved 2026-10-26)
- Results first posted: 2025-07-30 (ClinicalTrials.gov record NCT04755283, source copy `cardio:ctgov-nct04755283-2025-11-06`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Hungary; Poland; South Korea; Taiwan (ClinicalTrials.gov record NCT04755283, source copy `cardio:ctgov-nct04755283-2025-11-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04755283-2025-11-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
- Acronym: AZALEA-TIMI 71
- Condition: Atrial Fibrillation (AF)
- Condition: Stroke
- Intervention (Biological): Abelacimab
- Intervention (Drug): Rivaroxaban
- Lead sponsor: Anthos Therapeutics, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Novartis Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Anthos Therapeutics, Inc. (`cardio:org-anthos-therapeutics-inc`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation (`cardio:pubmed-39842011`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial (`cardio:pubmed-40546068`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial (`cardio:pubmed-41637102`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study (`cardio:pubmed-42213637`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c24778faeacf370f80a7fe12a1fcf857be93a94b7548347b8078142ce71f422e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
